Renalpharma

RenalPharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing and commercializing innovative therapies for chronic kidney disease (CKD) and its complications. The company's strategy focuses on licensing late-stage assets for the Chinese market alongside internal R&D efforts. Its lead program, Kiklin (RP-101), is a non-calcium, non-metal phosphate binder licensed from Sanwa Kagaku Kenkyusho, currently in Phase 3 trials for hyperphosphatemia. RenalPharma is also developing Enaroy (RP-601), an oral HIF-PH inhibitor licensed from Japan Tobacco for the treatment of renal anemia, which is also in Phase 3 development. Backed by prominent investors such as Lilly Asia Ventures and Matrix Partners China, the company is positioned as a leader in the specialized nephrology space in China.